Get the Stockscreener App
0.4973
1.23%
-0.0062
Atyr Pharma Inc stock is traded at $0.4973, with a volume of 252.66K.
It is down -1.23% in the last 24 hours and down -6.03% over the past month.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
See More
Previous Close:
$0.5035
Open:
$0.49
24h Volume:
252.66K
Relative Volume:
0.14
Market Cap:
$48.78M
Revenue:
$190.00K
Net Income/Loss:
$-70.03M
P/E Ratio:
-0.6772
EPS:
-0.7343
Net Cash Flow:
$-59.30M
1W Performance:
-7.91%
1M Performance:
-6.03%
6M Performance:
-48.44%
1Y Performance:
-90.91%
1-Day Range:
$0.4872
$0.508
1-Week Range:
$0.475
$0.5431
52-Week Range:
$0.395
$6.50
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.4973 | 49.34M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III - Freedom Broker
aTyr Pharma Company Profile & Introduction - Moomoo
ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesFree Cash Flow Trends - vinanet.vn
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Layoff Tracker: Aura, Schrödinger trim workforces - BioSpace
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com India
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - moomoo.com
Levi & Korsinsky Urges aTyr (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - The National Law Review
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ATyr Pharma Announces Second Quarter 2026 Res - Moomoo
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - The Manila Times
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates - scanx.trade
ATYR Looks 13.6% Overvalued on GF Value™ as Cash Supports Develo - GuruFocus
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus - GuruFocus
ATyr Pharma Sees Funding Sufficient Into Late 2028 >ATYR - moomoo.com
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky - The National Law Review
ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - marketscreener.com
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Moomoo
ATyr Pharma Fiscal Q2 Loss Narrows - marketscreener.com
aTyr Pharma cuts 60% of workforce after Q2 results - Quiver Quantitative
Atyr Pharma: Q2 Earnings Snapshot - Barchart.com
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
aTyr Pharma Q2 net loss narrows - TradingView
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD - TradingView
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary - TradingView
aTyr Pharma Prioritizes Efzofitimod Program, Cuts Workforce 60% as FDA Feedback on Phase 3 Sarcoidosis Study Protocol Looms - Quiver Quantitative
ATyr Pharma, Inc. Announces CFO Changes - marketscreener.com
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership - Stock Titan
ATYR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390 - tradingkey.com
ATYR Stockholders Have Opportunity to Lead aTyr Pharma, Inc. Clas - The National Law Review
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn - marketscreener.com
BRIEF-aTyr Pharma Q2 Net Income USD 19.531 Million - TradingView
aTyr Pharma Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19%Earnings Surprise Score - vinanet.vn
aTyr Pharma (ATYR) Rises 1.25% as Shares Defend Key $0.47 Support LevelTrading Ideas - vinanet.vn
LIFE|aTyr Pharma Ord Shs|Price:20.500|Chg%:+0.080 - TradingKey
ATYR Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite No RevenuePerformance Review - Vinanet
I am an 18-year-old ... - marketscreener.com
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (ATYR holder) reports 1.8% beneficial stake in aTYR PHARMA INC - Stock Titan
ATYR|aTyr Pharma Inc|Price:0.486|Chg%:+0.006 - TradingKey
aTyr Pharma Inc (ATYR) Cash Flow - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma (ATYR) Edges Higher Amidst Quiet Trading; Key Resistance in FocusActive ETF Flow - vinanet.vn
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma, Inc. Revenue Breakdown – NASDAQ:ATYR - TradingView
Atyr Pharma Inc Stock (ATYR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):